Michael Reale
Manchester, CTNPI 1992774434
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), consulting fees and education — rather than concentrated in one kind of arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.8%. Reporting peaked in 2019 at $1,308 and has fallen 81.3% since, to $244 in 2022.
Across 105 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$421
- Novocure GmbH$200
- GSK$135
- Merck$112
- Sanofi-aventis U.S. LLC$111
- Novartis$109
- plus $1K from 30 others
Across 16 payments — averaging $3108.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$46K
- E.r. Squibb & Sons, L.L.C.$4K
What the payments were for
- Consulting fees$63527%
- Speaking & faculty fees$2008%
- Food & beverage$1,28054%
- Education$25111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $421 |
| Novocure GmbH | 1 | $200 |
| GSK | 1 | $135 |
| Merck | 9 | $112 |
| Sanofi-aventis U.S. LLC | 2 | $111 |
| Novartis | 8 | $109 |
| E.r. Squibb & Sons, L.L.C. | 8 | $108 |
| Johnson & Johnson(2 entities) | 8 | $106 |
| Comsort, Inc | 1 | $100 |
| Amgen | 5 | $88 |
| Genentech USA, Inc. | 6 | $84 |
| Pfizer | 6 | $79 |
| AstraZeneca(2 entities) | 5 | $79 |
| Incyte Corporation | 4 | $60 |
| Bayer | 4 | $60 |
| Lilly USA, LLC | 4 | $57 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Seagen Inc. | 3 | $40 |
| Karyopharm Therapeutics Inc. | 3 | $37 |
| Sanofi | 2 | $30 |
| Bristol Myers Squibb | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Astellas Pharma US Inc | 2 | $29 |
| Gilead | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Tesaro, Inc. | 1 | $23 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Fortovia Therapeutics, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Heron Therapeutics, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| EMD Serono, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 22 | $324 |
| Hydroxyurea | 15 | $269 |
| Acyclovir | 13 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Acyclovir | $12 | $19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.